News from the Bench
Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.
Our U.S. Offices Are Closed
Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, December 1st.
Thank you for your patience.
To Purchase # 9841S
Find answers on our FAQs page.
PTM information and tools available.
Bisindolylmaleimide I, Hydrochloride #9841
Western blot analysis of extracts from A172 cells, untreated or treated with indicated concentrations of Bisindolylmaleimide I for 30 minutes, followed by stimulation with 200 nM TPA for 10 minutes. The phosphorylation of PEA-15 was detected by using Phospho-PEA-15 (Ser104) Antibody #2776 (upper). PEA-15 Antibody #2780 was used as a loading control (lower). Bisindolylmaleimide I-mediated inhibition of TPA-induced PKC phosphorylation of PEA-15 at Ser104 is shown.Learn more about how we get our images
Gallery: Bisindolylmaleimide I, Hydrochloride #9841
Bisindolylmaleimide I is supplied as 500 μg powder. Store at or below -20ºC. Before use, dissolve powder in 0.28 ml DMSO to make a 4 mM bisindolylmaleimide I stock solution. For working concentrations of 2 μM-4 μM, dilute DMSO stock 1:2000 to 1:1000. Treat cells with the desired concentration for 30 minutes.Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
C25H24N4O2 • HCl
Bisindolylmaleimide I (BIS) is a potent inhibitor of PKC (1,2). In vitro the IC50 of BIS is 10-20 nM for PKCα/β/γ and 100-200 nM for PKCδ/ε isoforms. The in vitro IC50 for PKCζ is about 6 μM, indicating that BIS is a very weak inhibitor for this isoform. In in vivo cellular assays the IC50 of BIS for PKC is between 0.2-2 μM (1,3).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.